Category
Tafamidis
CAS Number
1184581-58-5
Molecular Formula
C₁₄H₉Cl₂NO₄
Molecular Weight
326.13 g/mol
Synonym

4-(3,5-dichlorobenzamido)-3-hydroxybenzoic acid; 4-(3,5-Aichlorobenzamido)-3-hydroxybenzoic Acid; Benzoic acid, 4-[(3,5-dichlorobenzoyl)amino]-3-hydroxy-; Benzoicacid,4-[(3,5-dichlorobenzoyl)amino]-3-hydroxy;4-[(3,5-dichlorobenzoyl)amino]-3-hydroxybenzoic acid

Keywords
Pharmaceutical Standards
Metabolites.
Impurities
slide.1
Purity:

Above - 95.0%

Technical Data:

We will provide complete documentation support for every Standard Material. All analytical reports such as ¹H NMR, ¹³C NMR, Mass, FT-IR, HPLC Purity/GC Purity/QNMR Purity, Water content by KF/ Loss on Drying/TGA (Thermo-gravimetric Analysis). Certificate of Analysis with potency report. Each Standard Material SER (Structure Elucidation Report) with NMR, Mass, IR spectral interpretation. This whole analytical document can be included in eCTD, ANDA, DMF submissions to regulatory agencies.

Tafamidis Impurity 3 is a specified process-related impurity associated with the manufacture or degradation of the medication Tafamidis, which is used for treating transthyretin amyloidosis. It is typically characterized and monitored during quality control to ensure the drug substance meets regulatory limits for safety and purity. Impurity 3 may arise from intermediate reactions, side products, or degradation pathways during synthesis or storage, and is identified using analytical techniques such as HPLC or LC-MS in pharmaceutical testing.